ARTICLE | Clinical News
TSE-424: Began Phase III trial
January 16, 2001 8:00 AM UTC
Ligand Pharmaceuticals Inc. (LGND), San Diego, Calif. Product: TSE-424 Business: Musculoskeletal Therapeutic category: Hormone replacement Target: Estrogen receptors Description: Tissue selective estr...